Literature DB >> 18206353

Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment.

Donald F Smee1, Brian B Gowen, Miles K Wandersee, Min-Hui Wong, Ramona T Skirpstunas, Thomas J Baldwin, Justin D Hoopes, Robert W Sidwell.   

Abstract

The causes of death from intranasal cowpox virus infections in mice remain unclear. Hypotheses include severe pneumonitis, hepatitis and/or hyperproduction of cytokines and chemokines. This work explores these hypotheses by studying the influence of low- and high-volume virus inocula on viral pathogenesis. BALB/c mice were infected intranasally with a syncytium-forming variant of cowpox virus in 5 microL or 50 microL volumes containing the same infectious virus challenge dose. The 50 microL infection produced a more rapidly lethal disease associated with severe pneumonitis, high lung and nasal virus titres and increased cytokine and chemokine levels in the lungs and nasal tissue, whilst liver infection was minimal. The 5 microL inoculum infection was also lethal, but the infection was primarily confined to the upper respiratory tract and included elevated nasal cytokine and chemokine levels. Levels of the pro-inflammatory cytokine interleukin-6 were particularly high in both infections. Treatment of the infections with cidofovir (100mg/kg/day for 2 days starting 24h after virus exposure) led to survival and suppression of tissue virus titres. Treatment reduced pneumonitis in the 50 microL infection and lessened cytokine hyperproduction in both infections. We conclude that a 5 microL volume inoculum of cowpox virus causes a lethal upper respiratory tract infection, whilst the 50 microL inoculum targets both upper and lower respiratory tracts, with excessive release of systemic pro-inflammatory factors. Cidofovir effectively treated both infections and slowed viral replication sufficiently to subdue the exaggerated release of pro-inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18206353      PMCID: PMC2367113          DOI: 10.1016/j.ijantimicag.2007.11.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  16 in total

Review 1.  Exotic emerging viral diseases: progress and challenges.

Authors:  Thomas W Geisbert; Peter B Jahrling
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

2.  TLR3 deletion limits mortality and disease severity due to Phlebovirus infection.

Authors:  Brian B Gowen; Justin D Hoopes; Min-Hui Wong; Kie-Hoon Jung; Kevin C Isakson; Lena Alexopoulou; Richard A Flavell; Robert W Sidwell
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

3.  Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection.

Authors:  Corinna W Knorr; Stanley D Allen; Anthony R Torres; Donald F Smee
Journal:  Antiviral Res       Date:  2006-05-30       Impact factor: 5.970

Review 4.  Cytokines and immunity to viral infections.

Authors:  I A Ramshaw; A J Ramsay; G Karupiah; M S Rolph; S Mahalingam; J C Ruby
Journal:  Immunol Rev       Date:  1997-10       Impact factor: 12.988

5.  Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.

Authors:  Donald F Smee; Robert W Sidwell; Debbie Kefauver; Mike Bray; John W Huggins
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.

Authors:  Debra C Quenelle; Deborah J Collins; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 7.  Biological functions of tumor necrosis factor cytokines and their receptors.

Authors:  Klaus Pfeffer
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

8.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice.

Authors:  J Neyts; E De Clercq
Journal:  J Med Virol       Date:  1993-11       Impact factor: 2.327

9.  Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

Authors:  Debra C Quenelle; Deborah J Collins; W Brad Wan; James R Beadle; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects.

Authors:  M Wachsman; B G Petty; K C Cundy; H S Jaffe; P E Fisher; A Pastelak; P S Lietman
Journal:  Antiviral Res       Date:  1996-03       Impact factor: 5.970

View more
  13 in total

1.  KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo.

Authors:  Sophie Duraffour; Robert Drillien; Kazuhiro Haraguchi; Jan Balzarini; Dimitri Topalis; Joost J van den Oord; Graciela Andrei; Robert Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

2.  Cowpox virus induces interleukin-10 both in vitro and in vivo.

Authors:  April H Spesock; Brice E Barefoot; Caroline A Ray; Daniel J Kenan; Michael D Gunn; Elizabeth A Ramsburg; David J Pickup
Journal:  Virology       Date:  2011-06-11       Impact factor: 3.616

3.  Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.

Authors:  Donald F Smee
Journal:  Future Virol       Date:  2013-09       Impact factor: 1.831

4.  In vivo activation of toll-like receptor-9 induces an age-dependent abortive lytic cycle reactivation of murine gammaherpesvirus-68.

Authors:  Catherine Ptaschinski; Joel Wilmore; Nancy Fiore; Rosemary Rochford
Journal:  Viral Immunol       Date:  2010-12       Impact factor: 2.257

5.  Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease.

Authors:  Reed F Johnson; Dima A Hammoud; Matthew G Lackemeyer; Srikanth Yellayi; Jeffrey Solomon; Jordan K Bohannon; Krisztina B Janosko; Catherine Jett; Kurt Cooper; Joseph E Blaney; Peter B Jahrling
Journal:  Virology       Date:  2015-03-14       Impact factor: 3.616

6.  Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox.

Authors:  Reed F Johnson; Srikanth Yellayi; Jennifer A Cann; Anthony Johnson; Alvin L Smith; Jason Paragas; Peter B Jahrling; Joseph E Blaney
Journal:  Virology       Date:  2011-08-15       Impact factor: 3.513

7.  Fatal disseminated cowpox virus infection in an adolescent renal transplant recipient.

Authors:  Paul Gazzani; Joanna E Gach; Isabel Colmenero; Jeff Martin; Hugh Morton; Kevin Brown; David V Milford
Journal:  Pediatr Nephrol       Date:  2016-10-28       Impact factor: 3.651

8.  Study of camelpox virus pathogenesis in athymic nude mice.

Authors:  Sophie Duraffour; Patrick Matthys; Joost J van den Oord; Tim De Schutter; Tania Mitera; Robert Snoeck; Graciela Andrei
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

9.  Cidofovir Activity against Poxvirus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Viruses       Date:  2010-12-22       Impact factor: 5.048

10.  Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals.

Authors:  Sophie Duraffour; Barbara Mertens; Hermann Meyer; Joost J van den Oord; Tania Mitera; Patrick Matthys; Robert Snoeck; Graciela Andrei
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.